BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 8840003)

  • 1. Interference of an activity assay of tissue-type plasminogen activator in human plasma by endogenous factors.
    Mukherjee M; Sembhi K; Kakkar VV
    Blood Coagul Fibrinolysis; 1996 Jun; 7(4):491-6. PubMed ID: 8840003
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Absence of synergism between tissue-type plasminogen activator (t-PA), single-chain urokinase-type plasminogen activator (scu-PA) and urokinase on clot lysis in a plasma milieu in vitro.
    Collen D; De Cock F; Demarsin E; Lijnen HR; Stump DC
    Thromb Haemost; 1986 Aug; 56(1):35-9. PubMed ID: 3095946
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bolus dose response characteristics of single chain urokinase plasminogen activator and tissue plasminogen activator in a dog model of arterial thrombosis.
    Badylak SF; Voytik S; Klabunde RE; Henkin J; Leski M
    Thromb Res; 1988 Nov; 52(4):295-312. PubMed ID: 3144052
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of a recombinant fusion protein of the finger domain of tissue-type plasminogen activator with a truncated single chain urokinase-type plasminogen activator.
    Gheysen D; Lijnen HR; Piérard L; de Foresta F; Demarsin E; Jacobs P; De Wilde M; Bollen A; Collen D
    J Biol Chem; 1987 Aug; 262(24):11779-84. PubMed ID: 3114253
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of a chimeric plasminogen activator consisting of amino acids 1 to 274 of tissue-type plasminogen activator and amino acids 138 to 411 of single-chain urokinase-type plasminogen activator.
    Lijnen HR; Nelles L; Van Hoef B; Demarsin E; Collen D
    J Biol Chem; 1988 Dec; 263(35):19083-91. PubMed ID: 3143723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Thrombolytic and pharmacokinetic properties of a recombinant chimeric plasminogen activator consisting of a fibrin fragment D-dimer specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Dewerchin M; Vandamme AM; Holvoet P; De Cock F; Lemmens G; Lijnen HR; Stassen JM; Collen D
    Thromb Haemost; 1992 Aug; 68(2):170-9. PubMed ID: 1412163
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Plasminogen activators (t-PA and u-PA) and plasminogen activators inhibitors (PAI-1 and PAI-2) in some myeloproliferative syndromes.
    Rość D; Kremplewska-Nalezyta E; Gadomska G; Zastawna E; Michalski A; Drewniak W
    Med Sci Monit; 2000; 6(4):684-91. PubMed ID: 11208392
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of a recombinant chimeric plasminogen activator composed of a fibrin fragment-D-dimer-specific humanized monoclonal antibody and a truncated single-chain urokinase.
    Vandamme AM; Dewerchin M; Lijnen HR; Bernar H; Bulens F; Nelles L; Collen D
    Eur J Biochem; 1992 Apr; 205(1):139-46. PubMed ID: 1313361
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Synergy of in vitro thrombolytic action of combinations of recombinant staphylokinase and single-chain urokinase-type plasminogen activator.
    Aisina RB; Moukhametova LI; Varfolomeyev SD
    Biochemistry (Mosc); 2003 Nov; 68(11):1252-60. PubMed ID: 14640969
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Properties of chimeric (tissue-type/urokinase-type) plasminogen activators obtained by fusion at the plasmin cleavage site.
    Colucci M; Cavallo LG; Agnelli G; Mele A; Bürgi R; Heim J; Semeraro N
    Thromb Haemost; 1993 May; 69(5):466-72. PubMed ID: 8391727
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A specific immunologic assay for functional plasminogen activator inhibitor 1 in plasma--standardized measurements of the inhibitor and related parameters in patients with venous thromboembolic disease.
    Philips M; Juul AG; Selmer J; Lind B; Thorsen S
    Thromb Haemost; 1992 Nov; 68(5):486-94. PubMed ID: 1455392
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An enzyme-linked immunosorbent assay for urokinase-type plasminogen activator (u-PA) and mutants and chimeras containing the serine protease domain of u-PA.
    Declerck PJ; Van Keer L; Verstreken M; Collen D
    Thromb Haemost; 1992 Jan; 67(1):95-100. PubMed ID: 1377417
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of the effects of fibrin binding on the biochemical properties of single-chain tissue-type plasminogen activator (t-PA) and single-chain chimeric plasminogen activator (t-PA/scu-PA).
    Fischer BE
    Blood Coagul Fibrinolysis; 1992 Feb; 3(1):39-46. PubMed ID: 1320415
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Plasminogen activator inhibitor 2 and urokinase-type plasminogen activator in plasma and leucocytes in patients with severe sepsis.
    Robbie LA; Dummer S; Booth NA; Adey GD; Bennett B
    Br J Haematol; 2000 May; 109(2):342-8. PubMed ID: 10848822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasminogen activator in acute myeloid leukaemic marrows: u-PA in contrast to t-PA in normal marrow.
    McWilliam N; Robbie L; Booth N; Bennett B
    Br J Haematol; 1998 Jun; 101(4):626-31. PubMed ID: 9674732
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The nature of synergy between tissue-type and single chain urokinase-type plasminogen activators.
    Fry ET; Mack DL; Sobel BE
    Thromb Haemost; 1989 Nov; 62(3):909-16. PubMed ID: 2512679
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Conjugation to antifibrin Fab' enhances fibrinolytic potency of single-chain urokinase plasminogen activator.
    Bode C; Runge MS; Schönermark S; Eberle T; Newell JB; Kübler W; Haber E
    Circulation; 1990 Jun; 81(6):1974-80. PubMed ID: 2111744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of tissue plasminogen activator activity by aspirin in vivo and its relationship to levels of tissue plasminogen activator inhibitor antigen, plasminogen activator and their complexes.
    Levin RI; Harpel PC; Harpel JG; Recht PA
    Blood; 1989 Oct; 74(5):1635-43. PubMed ID: 2529003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Fibrinolytic changes in a patient with toxic shock syndrome; release of active u-PA.
    Haj MA; Robbie LA; Croll A; Adey GD; Bennett B
    Intensive Care Med; 1998 Mar; 24(3):258-61. PubMed ID: 9565810
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nonradical oxidants of the phagocyte type induce the activation of plasmatic single chain- urokinase.
    Stief TW; Stief MH; Ehrenthal W; Darius H; Martin E
    Thromb Res; 1991 Dec; 64(5):597-610. PubMed ID: 1808764
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.